TLM-021

TLM-021 is a preclinical-stage pharmaceutical candidate developed by Tsubota Laboratory for the suppression of myopia progression. Tsubota Laboratory, an ophthalmology-focused research and development company originating from Keio University School of Medicine, specializes in addressing the global rise in myopia through both medical devices and pharmacological interventions. TLM-021 is part of a drug discovery pipeline aimed at slowing the axial elongation of the eye, which is the primary structural cause of nearsightedness. While specific molecular target details for TLM-021 are not widely disclosed, the program leverages the company's expertise in the signaling pathways that regulate eye growth, such as those influenced by environmental light factors and early growth response protein 1 (EGR1).